CSF levels of angiogenesis-related proteins in patients with leptomeningeal metastases

Neurology

Volumn 65, Issue 7, 2005, Pages 1120-1122

  Reijneveld, J C ^a,e   Brandsma, D ^a   Boogerd, W ^c   Bonfrer, J G M ^c   Kalmijn, S ^a   Voest, E E ^a   Geurts Moespot, A ^b   Visser, M C ^e   Taphoorn, M J B ^a,d  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^d MEDICAL CENTER HAAGLANDEN   (Netherlands)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

UROKINASE; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BRAIN METASTASIS; CANCER SURVIVAL; CEREBROSPINAL FLUID LEVEL; CONTROLLED STUDY; CYTOLOGY; FEMALE; HUMAN; LEPTOMENINGEAL METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SURVIVAL TIME;

EID: 26444517768     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000178981.39984.c2     Document Type: Article

References (10)

1. DeAngelis LM. Current diagnosis and treatment of leptomeningeal metastasis. J Neurooncol 1998;38:245-252.
2. Herrlinger U, Wiendl H, Renninger M, Forschler H, Dichgans J, Weller M. Vascular endothelial growth factor (VEGF) in leptomeningeal metastasis: diagnostic and prognostic value. Br J Cancer 2004;91:219-224.
3. Siegal T. Leptomeningeal metastases: rationale for systemic chemotherapy or what is the role of intra-CSF-chemotherapy? J Neurooncol 1998; 38:151-157.
4. Reijneveld JC, Taphoorn MJB, Kerckhaert OAJ, Drixler TA, Boogerd W, Voest EE. Angiostatin prolongs the survival of mice with leptomeningeal metastases. Eur J Clin Invest 2003;33:76-81.
5. Reijneveld JC, Voest EE, Taphoorn MJB. Angiogenesis in malignant primary and metastatic brain tumors. J Neurol 2000;247:597-608.
6. Grebenschikov N, Geurts-Moespot A, De Witte H, et al. A sensitive and robust assay for urokinase and tissue-type plasminogen activators (uPA and tPA) and their inhibitor type I (PAI-1) in breast tumor cytosols. Int J Biol Markers 1997;12:6-14.
7. Span PN, Grebenchtchikov N, Geurts-Moespot J, Westphal JR, Lucassen AM, Sweep CG. EORTC Receptor and Biomarker Study Group Report: a sandwich enzyme-linked immunosorbent assay for vascular endothelial growth factor in blood and tumor tissue extracts. Int J Biol Markers 2000;15:184-191.
8. Akenami FO, Siren V, Koskiniemi M, Siimes MA, Teravainen H, Vaheri A. Cerebrospinal fluid activity of tissue plasminogen activator in patients with neurological diseases. J Clin Pathol 1996;49:577-580.
9. Hsu DW, Efird JT, Hedley-Whyte ET. Prognostic role of urokinase-type plasminogen activator in human gliomas. Am J Pathol 1995;147:114-123.
10. Stockhammer G, Poewe W, Burgstaller S, et al. Vascular endothelial growth factor in CSF: a biological marker for carcinomatous meningitis. Neurology 2000;54:1670-1676.